Introduction
Found widespread in plants and microorganisms, iminosugars were first isolated and synthesized in the1 960s. [1, 2] They differ from monosaccharides in that the endocyclic oxygen atom is replaced by ab asic nitrogen and that they lack the anomeric hydroxy group (Figure 1 ). Iminosugars mimic carbohydrates or their hydrolysis transition state [3] [the intermediate glycosyl (oxycarbenium) cation or the protonated glycoside] and therefore often inhibit carbohydrate-processinge nzymes such as glucosidases. With the development of better insight into glyAnalogues of N-butyl-1-deoxynojirimycin (NB-DNJ) were prepared and assayedf or inhibition of ceramide-specific glucosyltransferase (CGT), non-lysosomal b-glucosidase2 (GBA2) and the lysosomal b-glucosidase 1( GBA1). Compounds 5a-6f, which carry sterically demanding nitrogen substituents, and compound 13,d evoid of the C3 and C5 hydroxy groupsp resent in DNJ/NB-DGJ (N-butyldeoxygalactojirimycin) showed no inhibitory activityf or CGT or GBA2. Inversion of stereochemistry at C4 of N-(n-butyl)-and N-(n-nonyl)-DGJ (compounds 24) also led to al oss of activity in these assays.T he aminocyclopentitols N-(n-butyl)-(35 a), N-(n-nonyl)-4-amino-5-(hydroxymethyl)cyclopentane- (35 b) , and N-(1-(pentyloxy)methyl)adamantan-1-yl)-1,2,3-triol( 35 f), weref ound to be selective inhibitors of GBA1 and GBA2 that did not inhibitC GT (> 1mm), with the exception of 35 f,w hich inhibited CGT with an IC 50 value of 1mm.T he N-butyl analogue 35 a was 100-fold selective for inhibiting GBA1 over GBA2 (K i values of 32 nm and 3.3 mm for GBA1 and GBA2, respectively). The N-nonyla nalogue 35 b displayed a K i value of ! 14 nm for GBA1 inhibition and a K i of 43 nm for GBA2. The N-(1-(pentyloxy)methyl)adamantan-1-yl) derivative 35 f had K i values of % 16 and 14 nm for GBA1 and GBA2,r espectively.T he related N-bis-substituted aminocyclopentitols were found to be significantly less potent inhibitors than their mono-substituted analogues. The aminocyclopentitol scaffold should hold promise for further inhibitor development.
cobiology,a ni ncreasing number of new targets have been identified in the search for new therapeutic interventions, [4, 5] and as ar esult iminosugars have been proposed as source of compounds from which therapeutic agentsc an be discovered. [5, 6] Based on the natural product deoxynojirimycin (DNJ, Figure 1 ), two marketed drugs have been developed:m iglitol for the treatment of type 2d iabetesa nd miglustat (N-butyl-1-deoxynojirimycin, NB-DNJ, Figure 1 ) for the treatment of the lysosomals toraged isorders Gaucher's and Nieman-Pick type 2 diseases. [7] Other iminosugars are in clinical trials for rare diseases such as Pompe's and Fabry's diseases. They also hold promise for the treatmento fc ancer, cystic fibrosis, Parkinson's and Alzheimer's diseases, as antibacterial agents, and for dengue viral infections. [7, 8] The glycosphingolipid metabolic pathwayi sr egulated by severalk ey enzymest hat can be inhibited by NB-DNJ:C GT (ceramide-specific glucosyltransferase, Figure 2a ), GBA1 (GBA, bglucocerebrosidase) al ysosomal glucosylceramidase ( Figure 2b) , GBA2 (b-glucosidase 2, non-lysosomal glucosylceramidase, and bile acid b-glucosidase, Figure 2b ), which is membrane bound. [9, 10] These enzymes catalyzet he synthesis and degradation of glucosylceramide.I nG aucher's disease an inherited deficiency of GBA1 leads to lysosomal accumulation of glycosphingolipids, whichc an be treated by inhibition of CGT with miglustat. Mutation of the GBA2 gene is the cause of hereditary spastic paraplegia and cerebellar ataxia.M iglitol is an a-glycosidase inhibitor that is used for the treatment of type 2 diabetes by preventing the digestiono fc arbohydrates into monosaccharides. In 2002, it was reported that NB-DNJ and Nbutyldeoxygalactonojirimycin (NB-DGJ,F igure 1) cause reversible infertility in male C57BL/6 mice. [11] Subsequents tudies, however,r evealed that these specific compounds were not active in other species, including humans. [12, 13] Inhibition of these enzymes was initially believed to cause unstablec ellular glucosylceramide levels in the testes, hence a dysfunction in glycosphingolipids biosynthesis, to which NB-DNJ'sm ale contraceptive effecti nm ice wasa ttributed. It was later reported that NB-DNJ and NB-DGJi nhibitG BA2 more potently than CGT,i ndicating that inhibition of GBA2 was most likely responsible for the observed contraceptive effect rather than the inhibition of CGT. [10] The search for inhibitors of the glycosphingolipids metabolic pathway enzymes relies largely on structure-activity relationship studies by synthesizinga nd screening iminosugar analogues( Figure 3 ). As documented in the literature, analogues of NB-DNJ showedl ow potency (micromolar inhibition) when tested as inhibitors of CGT. [14, 15] These studies revealed that an alkyl group on the nitrogen atom is crucial for inhibitory activity;t he inhibition increases with the increaseo ft he chain length. [15] The glucose-and galactose-derived iminosugars NB-DNJ and NB-DGJ are active compounds;therefore, the configuration at C5 appears not to be critical. [15, 16] N-Butyl-a-homo-nojirimycin and other C2 substituted analogues are inactive, indicating that the C2 positionn eeds to remain unsubstituted. [16] Methyl ether formation at the C4 hydroxy group is detrimental, suggesting that af ree hydroxy group at that positioni sn ecessary for enzyme inhibition. [15] Removal or acetylation of the hydroxy group of the C6 hydroxymethyl moiety resultsi nal arge decreasei na ctivity. [14] The effect of ring size modification of NB-DNJ analogues hasa lso been studied. Synthetic seven- [17, 18] and eight-membered [19] aza sugars were reported as inhibitors of CGT,a long with some members of ring contracted 4-membered [19] analogues, and ad eoxygenated, C-alkylated fivemembered iminosugar. [20] Ah ydrophobic nojirimycin derivative, N-[5-(adamantan-1-ylmethoxy)pentyl]-1-deoxynojirimycin (AMP-DNJ, AMP-DNM, Figure 1 ) possesses enhanced potency (> 100-fold) relative to NB-DNJ in inhibiting CGT. [21, 22] The highly lipophilic AMP-DNJ was also tested as an inhibitoro fG BA1 and GBA2 and dis- played selective inhibitory activity of 1.7 nm for GBA2 and about 50-200 nm for GBA2. [23, 24] AMP-DNJ has several promising biological effects. AMP-DNJ enhances insulin sensitivity in mice andr ats, thus represents al ead for the development of a type 2d iabetes treatment. [25] Miglustat [26] and AMP-DNJ also hold promise for the treatment of cystic fibrosis patients that carry the mutant delF508-CTRF protein, the most common mutation in cystic fibrosis patients. In one study,t he effect of miglustatw as attributed to the rescue of the delF508-CTRF protein by inhibiting its deglucosylation (inhibitiono fE Ra-1,2-glucosidase) and the subsequentd el508-CFTR/calnexin interaction, ap rocess that leads to protein degradation. [26] In other structure-activity studies, hydrophobic groups were tethered to six-and seven-membered DNJ analogues, [27, 28] which functioned as pharmacological chaperones to improvef olding of mutant GBA1 in Gaucher's disease and top romote GBA1 trafficking from the endoplasmic reticulum to the lysosome. [27] [28] [29] 
Results and Discussion
The sterically demanding hydrophobic adamantyl group is located at the distal positioninthe AMP-DNJ molecule andrelated derivatives; [30] however,t he effect of such ag roup proximal to the nojirimycin core is not known.Inour research, we therefore appended increasingly bulkier substituents (5a-c, Scheme1)t ot he nitrogen to analyze the effect of proximal sterically demanding substituents on inhibitory activity.Inaddition, an electron-withdrawing N-phenyl group (5d and 5e, Scheme 1) was introduced designed to probe the effect of decreasingb asicity of the nitrogen atom and potential interactions with p moieties in the enzyme active site. Additionally, an analogue containing a N-morpholinopiperidine group (5f, Scheme 1) was prepared as ap roximal sterically demanding group that is also electronically different.
DNJ analogues with modified N-substituentsw erep repared in four steps as outlined in Scheme 1.
[31] Diol 2 was prepared by LAH reduction from tetra-O-benzyl-d-glucopyranose (1)a nd then was oxidized under Swern conditions to yield an unstable keto aldehyde 3.T he crude keto aldehyde intermediate 3 was subjected to ad ouble reductive alkylation to yield tertiary amines 4.T he O-benzyl protecting groups were removed via hydrogenolysis to afford the analogues 5a-f.
To generate additional structure-activity relationship information that had not yet been explored, we prepared an analogue of NB-DNJ in which the C3 and C5 hydroxy groups were deleted (compound 13,S cheme 2) and the 4-epi derivatives of NB-DGJ (compounds 24 a and 24 b,S cheme 3).
For the synthesis of 3,5-dideoxya nalogue 13 (Method Ai n Scheme 2), we applied as ynthetic method developed in our group. [32] b-Amino acid 7 wasp reparedf rom amino acid derivative 6 via Arndt-Eistert homologation [33, 34] and was then converted into Weinreb amide 8.B ecause the directalkylation of 8 was slow and low yielding, we removed the Boc protecting Scheme1.Syntheses of N-substitutedD NJ analogues 5a-5f.
[a]
Scheme2.Synthesis of DNJ 3,5-dideoxy analogue 13.
ChemMedChem 2017, 12,1977 -1984 www.chemmedchem.org 2017 The Authors. Publishedb yWiley-VCH Verlag GmbH &Co. KGaA, Weinheim group to obtain the free amine, which was then subjected to reductivea lkylation to yield 9.B oc protection then furnished intermediate 10.Y none 11 was obtained upon treatment of 10 with ethynylmagnesium bromide. After removalo ft he N-Boc protecting group of 11 and subsequent treatment with K 2 CO 3 , ar apid ring closure occurred to yield key intermediate enaminone 12.At wo-step, one-flask reduction (sodium borohydride, followed by hydrogenolysis) of 12 completed the synthesis of the desired analogue 13.T he configuration of the 3-OH group was confirmed by comparing the NMR spectra of 13 with a sample derived from the commercially available pipecolic acid derivative 14 (Method Bi nS cheme 2). Although enantiopurity can be compromisedo ccasionally duringt he cyclization step to form the enaminone, [35] it was well preserved in intermediate 12.T he specific rotations of 13 prepared by Method Aw as compared with that of 13 prepared by MethodB,a nd they were [a] = À22, c = 0.75, MeOH,a nd [a] = À21, c = 0.97, MeOH, respectively,s uggesting that no racemization tookp lace during the cyclization reaction.
The syntheses of N-alkyl-4-epi-DGJ analogues 24 a and 24 b are shown in Scheme 3. N,O-Protected-d-serine 6 was converted into the corresponding Weinreb amide 15,f ollowedb yB oc deprotection,a nd N-allylation of intermediate 16 to furnish 17. Boc re-protection of 17 provided 18,w hich was subjected to treatment with vinylmagnesium bromide at low temperature to furnish ring-closing metathesis precursor 19.C yclic enone 20 was obtained using the second-generation Grubbs catalyst in ar ing-closing metathesis reaction. 1,2-Reduction of 20 under Luche conditions afforded allylic alcohol 21 as the exclusive product. Allylic alcohol 21 wasnext subjected to dihydroxylation under Upjohn conditions to yield triol 22 stereoselectively.D eprotection of the Boc group and subsequentr eductive alkylation gave N-alkyl triols 23 andhydrogenolysis provided desired products 24 a and 24 b.
As described below,t he novel analogues did not lead to potent inhibition of tested enzymes. We therefore decided to investigate as tructurally relatedb ut different scaffold. Aminocyclopentitols are known inhibitors of glucosidases and are considered carbohydrate mimics that are missing an oxygen atom in the furanose ring and that carry an exocyclic amino group. [36] While the mechanism of inhibition remains unclear,i t has been proposed that, similart ot he deoxynojirimycins, they are mimicking either the protonated glycoside [37, 38] or the intermediate glycosyl (oxycarbenium) cation.
[39] N-Alkylated aminocyclopentitol analoguesg enerally showed stronger inhibition than primary amines. [40] Regardless,n oa minocyclopentitols have been tested as inhibitors of CGT,G BA1, and GBA2. Thus, we designed and prepared aminocyclopentitols 35 that stereochemically resemble NB-DNJ (Scheme 4).
The synthesis of the aminocyclopentitols is showni n Scheme 4. The primary alcohol of methyl-a-d-glucopyranoside (25)w as protected as as ilyl ether [41] 26 and the three secondary hydroxy groups were protected as benzyl ethers to generate intermediate 27.T he TBS group was removed under acidic conditions, andt hen the unmasked primary alcohol intermediate 28 was converted into iodomethyl derivative 29.F ragmentation of 29 was performed under ultrasonic conditions to afford aldehyde 30.
[42] Treatmentofaldehyde 30 with hydroxylamine hydrochloride in warm methanol in the presence of sodiumb icarbonate provided the corresponding oxime 31 as am ixture of E and Z isomers. An intramolecular 1,3-dipolar cycloaddition [43, 44] of the crude oxime 31 in toluenea tr eflux furnished cis-fused isoxazolidine 32.T he NÀO bond was cleaved with activated zinc under acidic aqueous conditions [45] to provide amine 33.T he direct reductive alkylation reaction of free amine 33 with butyraldehyde and nonyl aldehydew as low yieldinga nd the reaction products were difficult to purify. Better yields and only mono-alkylated products were obtained when the HCl salt of 33 (Et 3 Nw as used to neutralize the reaction medium) was used, providing improved yields (49!73 % and 41!70 %, respectively) of 34 a and 34 b.S ubsequently, compounds 34 c-34 d were prepared using the same protocol. ChemMedChem 2017, 12,1977 -1984 www.chemmedchem.org 2017 The Authors. Publishedb yWiley-VCH Verlag GmbH &Co. KGaA, Weinheim the synthesis of compound 35 f,amino alcohol 33 was subjected to hydrogenolysis to furnish intermediate aminotriol 35 e, which was then reactedw ith 5-(adamantan-1-yl)methoxy)pentanal following ar eported procedure [46] and subjected to reductive amination to generate the targeted adamantyl 35 f.
Enzyme inhibition studies
The iminosugar analogues were assayed for CGT and GBA2 inhibitory activities as described in our previous publications (concentrations up to 1000 mm for both assays) and for other glycosidases with concentrations up to 100 mm). [19] The GBA1 enzymatic inhibition studies are detailedi nt he experimental section. NB-DNJ was used as the positive control in all assays.
NB-DNJ analogues 5a-5f(Scheme 1), bearing proximal sterically demandings ubstituents showedn oi nhibition of CGT or GBA2 at 1000 mm,i ndicating that such groups are detrimental to inhibitory activity( data not shown). The 3,5-dideoxya nalogue 13 (Scheme 2) prepared in this report also lacks inhibitory activity forC GT and GBA2, thus supporting earlier findings that tetra-hydroxy substitution is critical for the effective inhibitory activity of these iminosugar analogues. [47] Inversion of configuration of the 3-hydroxy group (analogues 24 a and 24 b, Scheme3)a lso resulted in loss of activity in our assays (1000 mm,d ata not shown). The aminocyclitols 35 did not inhibit CGT at concentrationsu pt o1 000 mm,w ith the exception of 35 f,w hich inhibited CGT with an IC 50 of 1000 mm.M ost of the aminocyclitols 35,h owever, significantly inhibited GBA2 ( Table 1 ). The N-butyl analogue 35 a exhibited 2-and1 5-fold increases in potency relative to NB-DGJ and NB-DNJ, respectively.T hisp otencyw as enhanced with the increase in exocyclic N-alkyl chain length. Compound 35 b,i nw hich the nitrogen carries an onyl group, provided approximately 200-and 1000-fold increases in potencyc ompared with control compounds NB-DGJ and NB-DNJ, respectively.N otably, 35 b possesses > 10 000-fold selectivity for GBA2 (K i = 0.043 mm)o ver CGT,a si td id not inhibit this enzyme at 1000 mm (data not shown). Compound 35 b is not as potent in inhibiting GBA2 as AMP-DNJ (IC 50 = 1.0 nm)b ut it is ac omparatively am ore selective inhibitor for GBA2 than for CGT. [30] AMP-DNJ is 200 times more activea gainst GBA2 than CGT. [30] However,s everal other adamantyl-functionalized DNJ analogues are known that are also highly potent and highly selectivef or GBA2 over CGT. [48] Bis-substitution at the nitrogen significantly decreased inhibitory activity.T he di-butyl analogue 35 c and the di-nonyl analogue 35 d inhibited GBA2 with K i values of 95 and 0.89 mm,r espectively.T he most potent inhibitor was 35 f,c arrying the 1-((pentyloxy)methyl)adamantan-1-yl moiety at the nitrogen. Compound 35 f inhibited GBA2 with a K i of 0.014 mm and the IC 50 for CGT was 1000 mm (data not shown). This compound did not inhibit a-galactosidase, b-galactosidase, a-mannosidase and b-mannosidase at 100 mm.T hus, aminocyclitols 35 b and 35 f are among the most selectivei nhibitors of GBA2 over CGT reported to date. We further evaluated the inhibitory properties of the new iminosugars towardo ther readily available carbohydrate-processinge nzymes, a-glucosidase( Saccharomyces cerevisiae)a nd b-glucosidase (almond), a-galactosidase (green coffee beans), b-galactosidase (Escherichia coli), amannosidase (jack bean), and b-mannosidase (Romans nail) as described previously. [19] We found that aminocyclopentitols 35 a, 35 b and 35 f showed activity in the glucosidase assays ( Table 1) ChemMedChem 2017, 12,1977 -1984 www.chemmedchem.org 2017 The Authors. Publishedb yWiley-VCH Verlag GmbH &Co. KGaA, Weinheim also the most potent compound in these assays and inhibited a-glucosidase with a K i of 0.30 mm and b-glucosidase with a K i of 4.3 mm.H owever,a ll three compounds (35 a, 35 b,a nd 35 f) are more selective forG BA2 inhibition. The three derivatives did not show inhibitory activity for a-galactosidase, a-mannosidase, and b-mannosidase at ac oncentration of 100 mm (data not shown).
Aminocyclitols 35 a and 35 f were next tested for inhibition of recombinant human lysosomal b-glucosidase 1( GBA1) to determine compound selectivity. NB-DNJ and NB-DGJ were used as reference compounds andh ad K i valueso f34 mm and > 1mm,r espectively (Table 1) . Under the assay conditions used, NB-DNJ (IC 50 = 74 mm)w as a % 5-to 7-fold more potent inhibitoro fG BA1 compared to previously reported IC 50 values, which ranged from 400 to 520 mm. [23, 49, 50] NB-DGJ (1 mm)d id not inhibit GBA1, whichi sc onsistent with two of the three previously reported IC 50 valueso f3 20 mm, [50] > 1mm, [49] and > 3mm. [24] The N-butyl iminosugar 35 a was > 1000-fold more potent than NB-DNJ and was % 100-fold more potent an inhibitor of GBA1 than GBA2 with a K i of 32 nm.T his findingc ompares favorably to ar ecently reported selectiveG BA1 inhibitor based on ah ydroxylated pyrrolidine scaffold, which was a4 5-fold selective2 .0 mm inhibitor of GBA1. [51] The nonyli minosugar 35 b appears to titrate the GBA1 enzyme presenti nt he assay,producing complete inhibition of the enzymeatits nominal concentration of 14 nm.S imilarly,t he adamantyl iminosugar 35 f has am easured IC 50 value of % 16 nm,a pproximating the nominal GBA1 concentration. Therefore, the inhibitory potencies of both 35 b and 35 f cannot be accurately determined in this assay.I na ddition, both iminosugars 35 b and 35 f produce bi-phasice nzyme inhibition curves, in contrastt oNB-DNJ and 35 a,w hich both inhibit GBA1 monophasically. Although the reason for the biphasic 35 b and 35 f behaviori sn ot known,i ti sp ossible that 35 b and 35 f discriminate between two forms of the enzyme presenti na pproximately equal proportionsint he enzyme preparation.For example, 35 a and 35 f Table 1 . Inhibitoryactivity of iminosugar analogues on human recombinant GBA1, LE rat testicular GBA2, and a-and b-glucosidases. [a,b] Compound [a] The details of the enzyme inhibition study for GBA2, a-glycosidase, and b-glycosidase are the same as described in reference [19] . 
Conclusions
In summary,i minosugar analoguesw ith different structural modifications were prepared and assayed for aselection of carbohydrate-processing enzymes.T he DNJ analogues 5a-5f with sterically demanding substituents at the nitrogena tom, the 3,4-dideoxy analogue 13,a nd the 4-epi-DGJ analogues 24 did not inhibitC GT andG BA2 (tested up to 1000 mm). Analogues 35 a, 35 b and 35 f showed potent inhibition of GBA1 and GBA2 with K i values of 69 nm, < 14 nm,a nd 16 nm,r espectively.C ompound 35 a is a3 2nm inhibitor of GBA1 and 100-fold more potent for GBA1 inhibition than for GBA2.C ompound 35 a is % 1000-fold morep otent than NB-DNJ for inhibition of GBA1. The aminocyclopentitol analogues 35 did not inhibit CGT (tested up to 1000 mm)w itht he exception of 35 f, which inhibited CGT with an IC 50 of 1mm.T he results from this study suggest that the aminocyclopentitol scaffold may hold promise for future inhibitor development.
Experimental Section
Chemistry:
1 HNMR spectra were recorded using 400 MHz or 500 MHz spectrometers. 13 CNMR spectra were recorded using a 100 MHz or a1 25 MHz spectrometer.A ll chemical shifts were recorded as parts per million (ppm), and all samples were dissolved in CDCl 3 using the residual solvent peak as internal standard unless otherwise noted. Mass spectra were obtained from aZ AB HS mass spectrometer equipped with an 11/250 data system. Fast-atom bombardment mass spectrometry (FAB-MS) experiments were performed with aX enon gun operated at 8keV energy and 0.8 mA emission. Fast-atom bombardment high-resolution mass spectrometry (FAB-HRMS) data were recorded at 1:10 000 resolution using linear voltage scans under data system control and collected in a multi-channel analyzer mode (MCA). Ar ecording infrared spectrophotometer or an FTIR was used to record IR spectra. Optical rotations were obtained using ap olarimeter at room temperature. Melting points are uncorrected. All moisture-sensitive reactions were performed using either oven or flame dried glassware under ap ositive pressure of argon unless otherwise noted. Solvents and reagents that are commercially available were used without further purification unless otherwise noted. Te trahydrofuran and diethyl ether were freshly distilled from sodium benzophenone ketyl under argon or dried by passing the solvent through ad rying column. Methylene chloride was distilled freshly from calcium hydride under argon or dried by passing the solvent through a drying column. Silica gel (230-400 mesh) was used for flash column chromatography.A ll compounds were concentrated using as tandard rotary evaporator and high-vacuum techniques. The purity of compounds 35 a (95 %), 35 b (> 95 %), 35 c (> 95 %), 35 d (> 95 %), and 35 f (> 95 %) was determined by HPLC using an evaporative light scattering detector (ELSD).
Enzyme assays:T he enzyme preparation and enzymatic assays for GBA2 and CGT were carried out as described in detail previously by us. [19] GBA1 activity was measured using recombinant GBA1 enzyme (R&D Systems) and 2.5 mm 4-methlyumbelliferyl-b-glucoside (4-MU-b-glucoside) (Sigma) as substrate in 32.5 mm MES, 4mm CaCl 2 buffer,p H6.5. The substrate mix and inhibitors were pre-incubated on ice in a9 6-well plate and the assay was started with GBA1 (10 ng per well) addition (final volume 100 mL). The plate was incubated for 20 min at 37 8C. The enzymatic reactions were stopped with the addition of 0.3 m glycine/NaOH buffer, pH 10.1. The amount of liberated 4-methylumbelliferone was determined with aS pectromax fluorimeter (l ex = 365 nm/l em = 445 nm). As tandard curve of 4-methylumbelliferone (Sigma) was determined under the same experimental conditions. Ac oncentration-response of NB-DNJ was included in every experiment as positive control. Iminosugar IC 50 values were determined using Prism 6 (GraphPad) from concentration-response curves generated using at least eight concentrations in triplicate. For the biphasic inhibitor 35 f,I C 50 values were calculated for the high and low components using the biphasic function from 16 concentrations in triplicate. K i values were calculated using the Cheng-Prusoffequation.
Supporting information:S ynthesis procedures, spectroscopic data, and copies of 1 Ha nd 13 CNMR spectra of all new compounds. 
